Traditional Chinese medicine composition and application thereof

[0065] The preparation process of the traditional Chinese medicine composition of the present invention is to grind Hedyotis diffusa and Scutellaria barbata into powder, decoct with water for several times, combine the extracts, and concentrate them into extracts. The resulting extract was degreased with petroleum ether and extracted with ethyl acetate.

[0066] Subsequent drug efficacy experiments will prove that the traditional Chinese medicine composition of the present invention can replace chemotherapy drugs to prevent and treat breast cancer, osteoporosis, inflammation and inhibit the activity of tumor-related macrophages.

[0067] The traditional Chinese medicine composition of the present invention is a pure natural plant extract used both as medicine and food, and simultaneously exerts effects on breast cancer cell proliferation, tumor immune response cell activity, osteoclast differentiation and inflammation.

[0068] The traditional Chinese medicine composition of the

[0077] Embodiment 1 The preparation embodiment of Chinese medicine composition (YDW11) of the present invention

[0078] Take 500 grams of Hedyotis diffusa and 500 grams of Scutellaria barbata (compatibility at a weight ratio of 1:1), crush them, decoct them with water for 4 times, combine the extracts, concentrate to obtain 189.68 grams of extracts, and dissolve the obtained extracts in pure water , extracted 6 times with equal volume of petroleum ether for degreasing, the water phase was concentrated and freeze-dried to a constant weight of 134.6 grams, the degreased water extract was dissolved in pure water, and extracted 6 times with ethyl acetate to obtain an extract, which was concentrated Dried extract 0.28 g (YDW11)

[0079] Embodiment 2 The experimental research of Chinese medicine composition (YDW11) anti-breast cancer of the present invention

[0080] 2.1. MTT method to investigate the effect of YDW11 on the proliferation activity of normal human breast epithelial cells 10A1 and human breast cancer cell lines MDA-MB-231, BT549, and HS578T in vitro

[0081] 10A1 and MDA-MB-231 cells were seeded in 96-well plates at 5000 / 100 μL, BT549 cells were seeded at 2500 / 100 μL, and HS578T cells were seeded at 2000 / 100 μL in 96-well plates, and cultured overnight. YDW11 in 25, 50 μg·mL -1 Dosage treatment of cells, after treatment for 24H, 48H, and 72H, MTT was added to each well (dissolved in PBS to 5 mg·mL -1 ) 10 μL, continued to culture for 4 hours, discarded the supernatant, added 100 μL of DMSO, placed on a shaker until the crystals were completely dissolved, read the absorbance value A at 490 nm, and calculated the effect of each dose of YDW11 treatment groups on cell viability. Three rep